CClinicalTrials.gg
Sign In
CompletedNCT04822584BARVITUpdated Jun 12, 2026

Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

A Phase 2 interventional study of Baricitinib Oral Product and Placebo in Vitiligo, sponsored by University Hospital, Bordeaux. Completed at 4 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by University Hospital, Bordeaux · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this phase 2 study is to evaluate the effect and the safety of the combination of Baricitinib in combination with phototherapy in adult participants with non-segmental progressive vitiligo.

Read the detailed description

Treatment Strategy: Multicentric, parallel double blind randomized phase 2 prospective study comparing baricitinib (4mg/day) + narrowband UVB TL01 versus placebo + narrowband UVB TL01 Follow-up of the study: patients included in this study will start Baricitinib 3 months before starting narrowband UVB TL01. Phototherapy will be performed twice a week during 6 months. Follow-up visit will be done at week 12, 24, 36 and 48.

02

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • vitiligo
  • phototherapy
  • baricitinib
  • randomized
03

In context

Vitiligo

298 studies on the registry are indexed under Vitiligo; 69 are open to participants now.

This study's enrollment of 49 is above the median of 30 across 227 interventional studies indexed under Vitiligo.

Browse Vitiligo studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 783 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject: male or female aged ≥ 18 years and ≤ 75 years
  • Diagnosis of non-segmental (symmetrical) vitiligo with a body surface area involved >5% excluding hands and feet

  • Active non-segmental vitiligo is defined by:

    • Non-segmental vitiligo with new patches or extension of old lesions during the last 6 months AND
    • Presence of hypochromic aspect under Wood's lamp examination and/or perifollicular hypopigmentation under Wood's lamp examination.
  • Able to read, understand, and give documented (electronic or paper signature) informed consent
  • Registered in the French Social Security
  • Agree to discontinue the use of the following excluded medications/treatments for at least 4 weeks prior to randomization (Visit 2) and throughout the study: systemic steroids, phototherapy, methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine.

  • Agree to discontinue the use of the following excluded medications for at least 2 weeks prior to randomization (Visit 2) and throughout the study:

    • TCS or topical immune modulators (e.g., tacrolimus or pimecrolimus)
    • Topical phosphodiesterase type 4 (PDE-4) inhibitor (crisaborole)
    • Topical JAK inhibitor (e.g., tofacitinib or ruxolitinib) and/or any other investigational topical treatments.
  • Patient characteristics

  • Are male or nonpregnant, nonbreastfeeding female patients, except:

    1. Male patients must agree to use 2 forms of birth control (1 must be highly effective, see below) while engaging in sexual intercourse with female partners of childbearing potential while enrolled in the study and for at least 4 weeks following the last dose of investigational product.

    2. Female patients of childbearing potential must agree to use 2 forms of birth control, when engaging in sexual intercourse with a male partner while enrolled in the study and for at least 4 weeks following the last dose of investigational product.

      The following birth control methods are considered acceptable (the patient should choose 2 to be used with their male partner, and 1 must be highly effective):

      • Highly effective birth control methods: oral, injectable, or implanted hormonal contraceptives (combined estrogen/progesterone or progesterone only, associated with inhibition of ovulation); intrauterine device or intrauterine system (e.g., progestin-releasing coil); or vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate).
      • Effective birth control methods: condom with a spermicidal foam, gel, film, cream, or suppository; occlusive cap (diaphragm or cervical/vault caps) with a spermicidal foam, gel, film, cream, or suppository; or oral hormonal contraceptives.

    3. Females of nonchildbearing potential are not required to use birth control and they are defined as:

      • Women ≥60 years of age or women who are congenitally sterile, or
      • Women ≥40 and \<60 years of age who have had a cessation of menses for ≥12 months and a follicle-stimulating hormone (FSH) test confirming nonchildbearing potential (≥40 mIU/mL or ≥40 IU/L), or women who are surgically sterile (i.e., have had a hysterectomy or bilateral oophorectomy or tubal ligation).
  • Signed informed consent form (ICF)

Exclusion criteria

Exclusion Criteria:

  • Segmental or mixed vitiligo
  • Patients that are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus) that would interfere with evaluations of the effect of study medication on vitiligo
  • Patients who are currently experiencing a skin infection that requires treatment, or who are currently being treated with topical or systemic antibiotics.

Note: Patients may not be rescreened until at least 4 weeks after the date of their previous screen failure and at least 2 weeks after resolution of the infection.

  • Patients that have any serious concomitant illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring. (e.g., unstable chronic asthma).

  • Patients that have been treated with the following therapies:

    1. Monoclonal antibody (e.g., ustekinumab, omalizumab, dupilumab) for less than 5 half-lives prior to randomization.
    2. Received prior treatment with any oral JAK inhibitor (e.g., tofacitinib,ruxolitinib)
    3. Received any systemic corticosteroid administered within 4 weeks prior to planned randomization or are anticipated to require systemic corticosteroids during the study.
    4. Have had an intra-articular corticosteroid injection within 4 weeks prior to planned randomization.
    5. Have received more than 250 sessions of UV lights therapies.
  • Patients that are largely or wholly incapacitated permitting little or no self-care, such as being bedridden.
  • Patients that have uncontrolled arterial hypertension characterized by a repeated systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg in a seated position.
  • Patients that have had any major surgery within 8 weeks prior to screening or that will require major surgery during the study that, in the opinion of the investigator, would pose an unacceptable risk to the patient.
  • Patients that are immunocompromised and, in the opinion of the investigator, at an unacceptable risk for participating in the study.
  • Patients that have experienced any of the following event within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
  • Patients that have a history of recurrent (≥ 2) VTE or are considered at high risk of VTE as deemed by the investigator.
  • Patients that have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data.

  • Patients that have a history of lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for less than 5 years :

    1. Patients with cervical carcinoma in situ that has been resected with no evidence of recurrence or metastatic disease for at least 3 years may participate in the study.
    2. Patients with basal cell or squamous epithelial skin cancers that have been completely resected with no evidence of recurrence for at least 3 years may participate in the study.
  • Patients that have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection, including but not limited to the following:

Note: A recent viral upper respiratory tract infection or uncomplicatedurinary tract infection should not be considered clinically serious.

  1. symptomatic herpes zoster infection within 12 weeks prior to screening.
  2. history of disseminated/complicated herpes zoster (e.g., multidermatomal involvement, ophthalmic zoster, CNS involvement, or post-herpetic neuralgia).
  3. symptomatic herpes simplex at the time of randomization.
  4. active or chronic viral infection from hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
  5. household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB.
  6. evidence of active TB or have previously had evidence of active TB and did not receive appropriate and documented treatment.
  7. clinically serious infection or received intravenous antibiotics for an infection, within the past 4 weeks of randomization.

  8. any other active or recent infection within 4 weeks of randomization that, in the opinion of the investigator, would pose an unacceptable risk to the patient if participating in the study.

    • Patients that have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination).

Note: Patients eligible for herpes zoster vaccine, who have not received it prior to screening will be encouraged (per local guidelines) to do so prior to randomization; vaccination must occur >4 weeks prior to randomization and start of investigational product. Patients will be excluded if they were exposed to herpes zoster vaccination within 4 weeks of planned randomization.

Investigators should review the vaccination status of their patients and follow the local guidelines for vaccination of those ≥18 years of age with nonlive vaccines intended to prevent infectious disease prior to entering patients into the study

  • Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within the 2 years prior to screening.
  • Presence of significant uncontrolled neuropsychiatric disorder, are clinically judged by the investigator to be at risk for suicide.
  • Have donated more than a single unit of blood within 4 weeks prior to screening or intend to donate blood during the course of the study.

Other non inclusion criteria:

  • Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures.
  • Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have participated within the last 30 days in a clinical study involving an investigational product. If the previous investigational product has a long half-life (2 weeks or longer), at least 3 months or 5 half-lives (whichever is longer) should be allowed between the end of the previous treatment and the inclusion.
  • Have previously been randomized in this study or any other study investigating baricitinib.
  • Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

Diagnostic Assessments

  • Have screening electrocardiogram (ECG) abnormalities that, in the opinion of the investigator, are clinically significant and indicate an unacceptable risk for the patient's participation in the study.

  • Have evidence of active TB or latent TB:

    1. have evidence of active TB, defined in this study as the following:

      • Documented by a positive PPD test (≥5 mm induration between approximately 48 and 72 hours after application, regardless of vaccination history), medical history, clinical features, and abnormal chest x-ray at screening.
      • The QuantiFERON®-TB Gold test or T-SPOT®.TB test (as available and if compliant with local TB guidelines) may be used instead of the PPD test. Patients are excluded from the study if the test is not negative and there is clinical evidence of active TB.

Exception: Patients with a history of active TB who have documented evidence of appropriate treatment, have no history of re-exposure since their treatment was completed, and have a screening chest x-ray with no evidence of active TB may be enrolled if other entry criteria are met. Such patients would not be required to undergo the protocol-specific TB testing for PPD, QuantiFERON®-TB Gold test, or T-SPOT® TB test but must have a chest x-ray at screening.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Phototherapy associated with active treatment

    Baricitinib 4 mg/day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks. (Phototherapy will be started 12 weeks after the beginning of baricitinib)

    Drug: Baricitinib Oral Product

  • Placebo comparator
    Phototherapy associated with placebo

    Placebo once a day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks. (Phototherapy will be started 12 weeks after the beginning of placebo of baricitinib).

    Drug: Placebo

Interventions

  • DrugBaricitinib Oral Product

    Baricitinib 4 mg/day orally for 36 weeks

  • DrugPlacebo

    Placebo once a day orally for 36 weeks

06

What researchers measure

Primary outcomes

  1. Score with Vitiligo Area Scoring Index (VASI)

    The VASI Score is used to assess the severity and extent of Vitilgo. VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100). The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities \[excluding hands\], trunk, lower extremities \[excluding feet\], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.

    Time frame: week 36

Secondary outcomes

  1. Score with VASI score

    Change in percentage of repigmented Surface area 12 weeks after-inclusion, by using the VASI score at week 12. The VASI Score is used to assess the severity and extent of Vitilgo. VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100). The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities \[excluding hands\], trunk, lower extremities \[excluding feet\], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.

    Time frame: week 12

  2. Score with VASI score

    Change in percentage of repigmented Surface area 24 weeks after-inclusion, by using the VASI score at week 24. The VASI Score is used to assess the severity and extent of Vitilgo. VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100). The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities \[excluding hands\], trunk, lower extremities \[excluding feet\], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.

    Time frame: week 24

  3. Score with VASI score

    Change in percentage of repigmented Surface area 48 weeks after-inclusion, by using the VASI score at week 48. The VASI Score is used to assess the severity and extent of Vitilgo. VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100). The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities \[excluding hands\], trunk, lower extremities \[excluding feet\], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.

    Time frame: week 48

  4. Evaluation of Face Vitiligo Aera Scoring Index (F-VASI) score

    Mean variation in percentage of Face Vitiligo Aera Scoring Index (F-VASI) score between baseline , week 12

    Time frame: week 12

  5. Evaluation of Face Vitiligo Aera Scoring Index (F-VASI) score

    Mean variation in percentage of Face Vitiligo Aera Scoring Index (F-VASI) score between baseline , week 24

    Time frame: week 24

  6. Evaluation of Face Vitiligo Aera Scoring Index (F-VASI) score

    Mean variation in percentage of Face Vitiligo Aera Scoring Index (F-VASI) score between baseline , week 36

    Time frame: week 36

  7. Evaluation of Face Vitiligo Aera Scoring Index (F-VASI) score

    Mean variation in percentage of Face Vitiligo Aera Scoring Index (F-VASI) score between baseline , week 48

    Time frame: week 48

  8. Number of Adverse Events (AE) and serious adverse events (SAE), as well as the proportion of discontinuation due to AEs and/or SAEs

    AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related, that occurs after a subject provides informed consent. Abnormal laboratory values or test results occurring after informed consent constitute AEs only if they induce clinical signs or symptoms, are considered clinically meaningful, require therapy, or require changes in the study drug.

    Time frame: week 36

  9. Evaluation of score Vitiligo European Task Force (VETF)

    Variation of the score Vitiligo European Task Force (VETF) The VETF score is used to assess the severity and extent of vitiligo. The VETF assesses 3 dimensions of the disease in 5 areas (Head/neck, hands and feet, trunk, arms, legs) namely 1/ extent: percentage of vitiligo involvement estimated using the rule of nines, 2/ depigmentation severity grading (stage 0: normal pigmentation Stage 1: incomplete pigmentation , stage 2 complete depigmentation, stage 3: partial hair whitening \<30% stage 4: complete hair whitening) and 3/ spreading (score O: similar limits, Score 1: progressive vitiligo; score -1: regressive vitiligo).

    Time frame: Week 12

  10. Evaluation of score Vitiligo European Task Force (VETF)

    Variation of the score Vitiligo European Task Force (VETF) The VETF score is used to assess the severity and extent of vitiligo. The VETF assesses 3 dimensions of the disease in 5 areas (Head/neck, hands and feet, trunk, arms, legs) namely 1/ extent: percentage of vitiligo involvement estimated using the rule of nines, 2/ depigmentation severity grading (stage 0: normal pigmentation Stage 1: incomplete pigmentation , stage 2 complete depigmentation, stage 3: partial hair whitening \<30% stage 4: complete hair whitening) and 3/ spreading (score O: similar limits, Score 1: progressive vitiligo; score -1: regressive vitiligo).

    Time frame: Week 24

  11. Evaluation of score of the Vitiligo Extent Score (VES)

    Variation in percentage of the Vitiligo Extent Score (VES). The VES score is used to assess the severity and extent of vitiligo. Using the VES calculator www.vitiligo-calculator.com, investigator choose the pictures that best represent the patient's skin lesions and then the percentage of depigmented area is calculated.

    Time frame: Week 36

  12. Evaluation of score of the Vitiligo Extent Score (VES)

    Variation in percentage of the Vitiligo Extent Score (VES). The VES score is used to assess the severity and extent of vitiligo. Using the VES calculator www.vitiligo-calculator.com, investigator choose the pictures that best represent the patient's skin lesions and then the percentage of depigmented area is calculated.

    Time frame: Week 48

  13. Evaluation of score of the Vitiligo Signs of Activity Score (VSAS)

    Variation in percentage of the Vitiligo Signs of Activity Score (VSAS). The VSAS score is used to assess the activity of the disease. It is assessed by evaluating the number of location with at least one disease sign of activity.

    Time frame: Week 12

  14. Evaluation of score of the Vitiligo Signs of Activity Score (VSAS)

    Variation in percentage of the Vitiligo Signs of Activity Score (VSAS). The VSAS score is used to assess the activity of the disease. It is assessed by evaluating the number of location with at least one disease sign of activity.

    Time frame: Week 24

  15. Evaluation of score of the Vitiligo Signs of Activity Score (VSAS)

    Variation in percentage of the Vitiligo Signs of Activity Score (VSAS). The VSAS score is used to assess the activity of the disease. It is assessed by evaluating the number of location with at least one disease sign of activity.

    Time frame: Week 36

  16. Evaluation of score of the Vitiligo Signs of Activity Score (VSAS)

    Variation in percentage of the Vitiligo Signs of Activity Score (VSAS). The VSAS score is used to assess the activity of the disease. It is assessed by evaluating the number of location with at least one disease sign of activity.

    Time frame: Week 48

  17. Evaluation of score of the Dermatology Life Quality Index (DLQI)

    Variation of the score of the Dermatology Life Quality Index (DLQI). DLQI is a 10-item instrument, each item scored from 0 to 3 where higher scores correspond to worse symptom impact, full range from 0 to 30.

    Time frame: week 12

  18. Evaluation of score of the Dermatology Life Quality Index (DLQI)

    Variation of the score of the Dermatology Life Quality Index (DLQI). DLQI is a 10-item instrument, each item scored from 0 to 3 where higher scores correspond to worse symptom impact, full range from 0 to 30.

    Time frame: week 24

  19. Evaluation of score of the Dermatology Life Quality Index (DLQI)

    Variation of the score of the Dermatology Life Quality Index (DLQI). DLQI is a 10-item instrument, each item scored from 0 to 3 where higher scores correspond to worse symptom impact, full range from 0 to 30.

    Time frame: week 36

  20. Evaluation of score of the Dermatology Life Quality Index (DLQI)

    Variation of the score of the Dermatology Life Quality Index (DLQI). DLQI is a 10-item instrument, each item scored from 0 to 3 where higher scores correspond to worse symptom impact, full range from 0 to 30.

    Time frame: week 48

  21. Evaluation of the score of the Skindex 29

    Variation of the score of the Skindex 29. SkinDex29 is a 30-item instrument, each item scored from 1 to 5 where higher scores correspond to worse symptom impact, full range from 0 to 150.

    Time frame: Week 12

  22. Evaluation of the score of the Skindex 29

    Variation of the score of the Skindex 29. SkinDex29 is a 30-item instrument, each item scored from 1 to 5 where higher scores correspond to worse symptom impact, full range from 0 to 150.

    Time frame: Week 24

  23. Evaluation of the score of the Skindex 29

    Variation of the score of the Skindex 29. SkinDex29 is a 30-item instrument, each item scored from 1 to 5 where higher scores correspond to worse symptom impact, full range from 0 to 150.

    Time frame: Week 36

  24. Evaluation of the score of the Skindex 29

    Variation of the score of the Skindex 29. SkinDex29 is a 30-item instrument, each item scored from 1 to 5 where higher scores correspond to worse symptom impact, full range from 0 to 150.

    Time frame: Week 48

  25. Evaluation of blood inflammatory markers using immunofluorescence on skin biopsies and ELISA multiplex.

    Expression of IFN-α, TNF-α, IFN-γ, IL-4, IL-5, IL-12, IL-13, IL-15, IL-17, IL-22, IL-23, IL-33 CXCL4, CXCL9, CXCL10, CXCL11, CXCL12, CXCL16, CCL20, soluble HSP70.

    Time frame: day 1

  26. Evaluation of blood inflammatory markers using immunofluorescence on skin biopsies and ELISA multiplex.

    Expression of IFN-α, TNF-α, IFN-γ, IL-4, IL-5, IL-12, IL-13, IL-15, IL-17, IL-22, IL-23, IL-33 CXCL4, CXCL9, CXCL10, CXCL11, CXCL12, CXCL16, CCL20, soluble HSP70.

    Time frame: week 12

  27. Evaluation of blood inflammatory markers using immunofluorescence on skin biopsies and ELISA multiplex.

    Expression of IFN-α, TNF-α, IFN-γ, IL-4, IL-5, IL-12, IL-13, IL-15, IL-17, IL-22, IL-23, IL-33 CXCL4, CXCL9, CXCL10, CXCL11, CXCL12, CXCL16, CCL20, soluble HSP70.

    Time frame: week 36

07

Study locations

4 sites
  • Service de Dermatologie - Hôpital Saint-André
    Bordeaux, Bordeaux 33075, France
  • Service de dermatologie - Hôpital Henri Mondor - EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques)
    Créteil, 94010, France
  • Centre Hospitalier Universitaire de Nice - Service de Dermatologie
    Nice, 06000, France
  • Service de dermatologie Centre de Référence des Maladies Rares de la Peau et des muqueuses d'origine génétique - Hôpital Larrey
    Toulouse, 31059 cedex 9, France
08

References and documents

Publications

  • Seneschal J, Guyon M, Merhi R, Mazereeuw-Hautier J, Andreu N, Cazenave S, Ezzedine K, Passeron T, Boniface K. Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial. JAMA Dermatol. 2025 Apr 1;161(4):375-382. doi: 10.1001/jamadermatol.2024.5737. PubMed 39841460 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04822584
Lead sponsor
University Hospital, Bordeaux
Responsible party
Sponsor
First posted
Mar 30, 2021
Start date
Jul 16, 2021
Primary completion
Apr 26, 2023
Completion
Apr 26, 2023
Last update
Jun 12, 2026

Study contacts

Julien Seneschal, MD, PhD
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Vitiligo→

Other studies from this sponsor

University Hospital, Bordeaux

Start the discussion